JAMA news releases are made available to the public after 3 pm US Central time on the first 4 Tuesdays of each month. The Archives Journals news releases are made available to the public after 3 pm Central time on Mondays. We also provide a list of previous news releases.
THIS WEEK'S CONTENT
JAMA NEWS RELEASES
(Embargoed for Release: 3 p.m. CT, Tuesday, September 13, 2005)
JAMA NEWS RELEASES
MEDICATION-RELEASING STENT REDUCES RISK OF ARTERY RE-NARROWING FOLLOWING ANGIOPLASTY FOR PATIENTS WITH COMPLEX CORONARY ARTERY DISEASE
HIGH-DOSE RADIATION REDUCES RISK OF PROSTATE CANCER RECURRENCE
PATIENTS WITH HEART FAILURE AT GREATEST RISK OF DEATH LEAST LIKELY TO RECEIVE APPROPRIATE MEDICATIONS
INSURANCE STATUS AFFECTS ABILITY TO SECURE NECESSARY, TIMELY FOLLOW-UP MEDICAL APPOINTMENTS
STUDY REVEALS TRENDS IN U.S. DEATH RATE, LEADING CAUSES OF DEATH OVER 30 YEARS
JAMA REPORT (VIDEO NEWS RELEASE SCRIPT)
VIDEO: Windows Media | Quicktime
STENT COATED WITH DRUG CALLED PACLITAXEL MORE EFFECTIVE THAN BARE METAL STENTS IN TREATING SICKEST HEART PATIENTS
INFORMATION CONTAINED IN THESE NEWS RELEASES IS PROTECTED BY COPYRIGHT. JOURNAL ATTRIBUTION IS REQUIRED.
TV Note: This week's JAMA video news release is on the advantage of a stent that releases medication for patients with coronary artery disease. The release will be fed Tuesday, September 13, from 9:00 - 9:30 a.m. ET on Intelsat America 6 (formerly Telstar 6), Transponder 11 (C-Band) and from 2:00 - 2:30 p.m. ET on Intelsat America 6, Transponder 11 (C-Band). For more information, call 312/464-JAMA (5262).
JOURNALISTS CAN NOW ACCESS EMBARGOED JAMA/ARCHIVES STUDIES ONLINE
Go to www.jamamedia.org for more information and to apply for access.
Save the Dates:
September 16-18, Chicago
JAMA and BMJ will host the 5th International Congress on Peer Review and Biomedical Publication. New research will be released on topics including clinical trial registries, conflict of interest, scientific misconduct, bias in funding and sponsorship, and reporting clinical trials. For more information, go to www.jama-peer.org. To register, go to www.jamamedia.org and click on Events; email mediarelations{at}jama-archives.org; or call 312-464-JAMA (5262).
September 20, New York
JAMA will hold a media briefing on Medical Research - State of the Science, at Rockefeller University in New York on Tuesday, September 20, beginning at 9:30 a.m. A program will be included in a future email. To register, go to www.jamamedia.org and click on Events; email mediarelations{at}jama-archives.org; or call 312-464-JAMA (5262).
Please Note: The FOR THE MEDIA Web site now has a search feature to enable media to find previous JAMA/Archives news releases on specific medical topics. This search feature link is located on the home page at www.jamamedia.org
Embargoed for Release: 3 p.m. CT, Tuesday, September 13, 2005
Media Advisory: To contact Gregg W. Stone, M.D., call Tracy Hickenbottom at 212-305-5587.
To contact editorial co-author Antonio Colombo, M.D., email:
info{at}emocolumbus.it.
MEDICATION-RELEASING STENT REDUCES RISK OF ARTERY RE-NARROWING FOLLOWING ANGIOPLASTY FOR PATIENTS WITH COMPLEX CORONARY ARTERY DISEASE
CHICAGO—Compared to bare metal stents, placement of stents that release the medication paclitaxel reduces the risk of the artery re-narrowing nine months following angioplasty for patients with complex coronary artery lesions, according to an article in the September 14 issue of JAMA.
Drug-eluting stents have revolutionized the treatment of atherosclerotic coronary artery disease, according to background information in the article. These stents (which release medications, such as sirolimus and paclitaxel) have been shown to safely reduce clinical and angiographic restenosis (narrowing again of the artery after treatment) compared with bare metal stents. Enrollment in the trials for these stents, however, was restricted to relatively simple stenoses (vessel diameter of 2.5-3.75 mm with lesion length 30 mm or less). More than 55 percent of lesions currently treated with these bioactive devices may fall outside this range. The efficacy of drug-eluting stents has not been established for small vessels (in which the utility of stents as a class is still uncertain), large vessels (in which outcomes with bare metal stents are favorable), or in long lesions requiring multiple stents.
Gregg W. Stone, M.D., of Columbia University Medical Center and Cardiovascular Research Foundation, New York, and colleagues conducted a study (the TAXUS V trial) to investigate the safety and efficacy of a paclitaxel-eluting stent in a patient population with more complex coronary lesions than previously studied. The trial, conducted from February 2003 to March 2004 at 66 academic and community-based institutions, included 1,156 patients who underwent stent implantation in a single coronary artery stenosis (vessel diameter, 2.25-4.0 mm; lesion length, 10-46 mm), including 664 patients (57.4 percent) with complex or previously unstudied lesions (requiring 2.25-mm, 4.0-mm, and/or multiple stents) and had 9-month clinical and angiographic follow-up. Patients were randomly assigned to receive 1 or more bare metal stents (n = 579) or identical-appearing paclitaxel-eluting stents (n = 577).
The average reference vessel diameter was 2.69 mm, the reference lesion length was 17.2 mm. An average of 1.38 stents (total average length, 28.4 mm) were implanted per lesion. Stents of 2.25 mm and 4.0 mm in diameter were used in 18 percent and 17 percent of lesions, respectively; multiple stents were used in 33 percent of lesions.
"Compared with bare metal stents, implantation of paclitaxel-eluting stents reduced the 9-month rate of target lesion revascularization from 15.7 percent to 8.6 percent and target vessel revascularization from 17.3 percent to 12.1 percent. Among patients receiving the paclitaxel-eluting stent compared with a bare metal stent, the rate of in-stent restenosis was reduced with from 31.9 percent to 13.7 percent and analysis segment angiographic restenosis was reduced from 33.9 percent to 18.9 percent," the authors write.
"By multivariate analysis, randomization to the paclitaxel-eluting stent was an independent predictor of freedom from 9-month target lesion revascularization [2.2 times more likely], target vessel revascularization [1.7 times more likely], and restenosis [2.9 times more likely]. These benefits were achieved with comparable safety in both groups, with similar rates of cardiac death, myocardial infarction, and stent thrombosis at 1 and 9 months."
Angiographic restenosis was also reduced among patients receiving 2.25-mm stents (49.4 percent vs. 31.2 percent), 4.0-mm stents (14.4 percent vs. 3.5 percent), and multiple stents (57.8 percent vs. 27.2 percent).
"In conclusion, the TAXUS V trial investigated the use of paclitaxel-eluting stents in a patient population with more complex lesions than had been previously studied. Angiographic restenosis and target vessel revascularization were significantly reduced in the entire cohort, as well as in those patients with complex disease," the authors write.
(JAMA. 2005;294:1215-1223. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: This study was sponsored and funded by Boston Scientific Corp., Natick, Mass. For the financial disclosures of the authors, please see the JAMA article.
EDITORIAL: PACLITAXEL-ELUTING STENTS IN COMPLEX LESIONS
In an accompanying editorial, Antonio Colombo, M.D., and John Cosgrave, M.D., of the Columbus and San Raffaele Hospitals, Milan, Italy, comment on the study by Stone et al.
"It is becoming increasingly clear that drug-eluting stents have not abolished the restenotic process, and especially in high-risk lesions, target vessel revascularization rates exceed 10 percent. This suggests that while the two most studied stents are a vast improvement over the bare metal stent, there is still room for further progress. Perhaps thinner strut stents or drug combinations may hold the key to decrease restenosis even further. Finally, there is the huge challenge of reducing myocardial infarction and death following percutaneous coronary intervention and stent placement. The next step is to move from the complex lesion to the complex patient," the authors write.
(JAMA. 2005;294:1268-1270. Available pre-embargo to the media at www.jamamedia.org)
For More Information: Contact the JAMA/Archives Media Relations Department at 312/464-JAMA (5262) or email: mediarelations{at}jama-archives.org.
Go back to the top.
Embargoed for Release: 3 p.m. CT, Tuesday, September 13, 2005
Media Advisory: To contact Anthony L. Zietman, M.D., call Emily Parker at 617-724-6425.
To contact editorial co-author Theodore L. DeWeese, M.D., call Eric Vohr at 410-955-8665.
HIGH-DOSE RADIATION REDUCES RISK OF PROSTATE CANCER RECURRENCE
CHICAGO—Men with localized prostate cancer who received high-dose external radiation therapy were less likely to have cancer recurrence than men who received conventional-dose radiation therapy, according to an article in the September 14 issue of JAMA.
The majority of cases of prostate cancer now diagnosed in the United States are detected while the disease is still clinically localized, according to background information in the article. External beam radiation is one of the options used to treat more than 26,000 U.S. men annually. Failure after treatment with conventional radiation therapy is common, with a resultant increase in prostate-specific antigen (PSA) levels, secondary treatment, and, ultimately, clinical recurrence. Increasing the delivered radiation dose may increase the probability of local tumor control but carries a risk of greater adverse effects unless the volume of normal tissue treated along with the tumor can be reduced.
In the 1990s a number of computed tomography-based techniques became available to deliver radiation more accurately and thus allow the delivery of higher doses. These techniques are together known as "3-dimensional conformal therapy" and include the use of conformal photon beams, intensity-modulated photon beams, and proton beams.
Anthony L. Zietman, M.D., of Massachusetts General Hospital and Harvard Medical School, Boston, and colleagues conducted a study to determine whether tumor control could be improved in patients with prostate cancer, including those with low-risk disease, by the use of higher radiation doses. The study included 393 patients with stage T1b through T2b prostate cancer and prostate-specific antigen (PSA) levels less than 15 ng/mL, randomized between January 1996 and December 1999. The median (middle) value for PSA levels was 6.3 ng/mL, and the median follow-up time was 5.5 years. Patients received either external beam radiation to a total dose of either 70.2 Gy (radiation dose unit; conventional dose) or 79.2 Gy (high dose). This was delivered using a combination of conformal photon and proton beams.
The researchers found that the proportions of men free from biochemical failure (increasing PSA level) at 5 years were 61.4 percent for conventional-dose and 80.4 percent for high-dose therapy, a 49 percent reduction in the risk of failure. The advantage to high-dose therapy was observed in both the low-risk and the higher-risk subgroups (risk reduction, 51 percent and 44 percent, respectively). There has been no significant difference in overall survival rates between the treatment groups. Only 1 percent of patients receiving conventional-dose and 2 percent receiving high-dose radiation experienced acute urinary or rectal problems of Radiation Therapy Oncology Group (RTOG) grade 3 or greater. So far, only 2 percent and 1 percent, respectively, have experienced late problems having RTOG grade 3 or greater.
"This randomized trial shows that when men with clinically localized prostate cancer are treated with high-dose rather than conventional-dose external radiation therapy, they are more likely to be free from an increasing PSA level 5 years later and less likely to have locally persistent disease," the authors conclude.
(JAMA. 2005;294:1233-1239. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: This trial was supported by a grant from the National Cancer Institute.
EDITORIAL: RADIATION DOSE ESCALATION AS TREATMENT FOR CLINICALLY LOCALIZED PROSTATE CANCER — IS MORE REALLY BETTER?
In an accompanying editorial, Theodore L. DeWeese, M.D., and Danny Y. Song, M.D., of Johns Hopkins University School of Medicine, Baltimore, comment on the study and on radiation dose level for prostate cancer.
"Based on the study by Zietman et al, it is possible to now state with more certainty that higher radiation doses can be safely delivered to men with clinically localized prostate cancer and that this increased dose is associated with improved biochemical control of disease. However, whether this increase in PSA control will necessarily translate into improvement in clinically meaningful end points such as longer survival is not yet known. As such, this study has not answered the important question of whether patients should accept the modest but real incremental risk of higher radiation doses for the uncertain ultimate benefit derived."
"Several other questions also remain unanswered: (1) Would higher radiation doses beyond 79 Gy provide even greater benefit? (2) What is the optimal radiation method of dose escalation? and (3) Given that the addition of androgen suppression to radiotherapy has recently been shown to improve survival in some patients, is dose escalation even the best way to improve radiotherapeutic outcomes in this disease? Nevertheless, these randomized trial data support the use of higher radiation doses in men with lower-risk prostate cancer, and these findings will serve as an important foundation for future work," they write.
(JAMA. 2005;294:1274-1276. Available pre-embargo to the media at www.jamamedia.org)
For More Information: Contact the JAMA/Archives Media Relations Department at 312/464-JAMA (5262) or email: mediarelations{at}jama-archives.org.
Go back to the top.
Embargoed for Release: 3 p.m. CT, Tuesday, September 13, 2005
Media Advisory: To contact corresponding author Andreas Laupacis, M.D., M.Sc., call Julie Argles at 416-480-4780.
PATIENTS WITH HEART FAILURE AT GREATEST RISK OF DEATH LEAST LIKELY TO RECEIVE APPROPRIATE MEDICATIONS
CHICAGO—Even though certain medications such as ACE inhibitors reduce the risk of death for patients with heart failure, patients at greatest risk often are not prescribed these medications, according to an article in the September 14 issue of JAMA.
Heart failure affects more than 5 million people in Canada and the United States and is associated with a high death rate, according to background information in the article. Medications shown to reduce the risk of illness and death from this condition include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and beta-adrenoreceptor antagonists. These drug classes have been studied extensively and recommended strongly by disease management guidelines, given their proven benefit of reducing the risk of death in patients at the highest risk. It might be expected that these individuals would be more likely to receive these medications. However, previous studies have suggested that the opposite may occur in practice.
Douglas S. Lee, M.D., Ph.D., of the University of Toronto, and colleagues examined the use of drug therapies for heart failure in relation to predicted 1-year death rates. The patients for this study were part of the Enhanced Feedback for Effective Cardiac Treatment (EFFECT) study (1999-2001), which included 9,942 hospitalized patients with heart failure. The researchers evaluated 1,418 patients, aged 79 years or younger, with documented left ventricular ejection fraction (a measure of the heart's pumping ability) of 40 percent or less and with low-, average-, and high-predicted risk of death within 1 year. All patients survived to hospital discharge. Administration of ACE inhibitors, ACE inhibitors or ARBs, and beta-adrenoreceptor antagonists were evaluated according to predicted risk of death.
The researchers found that at hospital discharge, prescription rates for patients in the low-, average-, and high-risk groups were 81 percent, 73 percent, 60 percent, respectively, for ACE inhibitors; 86 percent, 80 percent, 65 percent, respectively, for ACE inhibitors or ARBs; and 40 percent, 33 percent, 24 percent, respectively, for beta-adrenoreceptor antagonists. Within 90 days following hospital discharge, the prescribing rates were 83 percent, 76 percent, and 61 percent for ACE inhibitors; 89 percent, 83 percent, and 67 percent for ACE inhibitors or ARBs; and 43 percent, 36 percent, and 28 percent for beta-adrenoreceptor antagonists for the three risk groups, respectively. The pattern of lower rates of drug administration in those patients at increasing risk was maintained up to 1 year postdischarge.
After accounting for varying survival time and potential contraindications to therapy, low-risk patients were 61 percent more likely to receive ACE inhibitors or ARBs; and 80 percent more likely to receive beta-adrenoreceptor antagonists compared with high-risk patients.
"A potential explanation for the inverse relationship between risk and treatment rates could be under appreciation of the benefits of therapy, particularly in patients with chronic disease who are at risk of death from noncardiac causes," the authors write. "Additionally, clinicians may be distracted from heart failure care in patients with multiple comorbid [coexistence of two or more often related diseases] conditions. However, despite excluding patients with several potential life-limiting comorbidities, the treatment mismatch remained. The possible need for multiple prescription medications could also be a consideration in withholding therapy."
"In conclusion, the predicted and observed risks of death in patients with heart failure were inversely associated with discharge and postdischarge administration of potentially life-saving drug therapies. This finding is particularly important because patients at highest risk of death have great need for effective treatment. Clinical use of quantitative multifactorial risk profiles or algorithms that convey information regarding probability of poor outcomes could be applied to better identify such patients. Further study is needed to quantify the adverse consequences attributable to the mismatch between risk and treatment rates and may also identify potential solutions to correct this undesirable phenomenon," the researchers write.
(JAMA. 2005;294:1240-1247. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: For funding/support information, please see the JAMA article.
For More Information: Contact the JAMA/Archives Media Relations Department at 312/464-JAMA (5262) or email: mediarelations{at}jama-archives.org.
Go back to the top.
Embargoed for Release: 3 p.m. CT, Tuesday, September 13, 2005
Media Advisory: To contact Brent R. Asplin, M.D., M.P.H., call Ashley Burt at 952-883-5304.
INSURANCE STATUS AFFECTS ABILITY TO SECURE NECESSARY, TIMELY FOLLOW-UP MEDICAL APPOINTMENTS
CHICAGO—Callers claiming to have private insurance were much more likely to receive a follow-up appointment within a week for an urgent medical condition than those with Medicaid coverage or without insurance, according to an article in the September 14 issue of JAMA.
According to background information in the article, U.S. residents will make approximately 114 million visits to hospital emergency departments (EDs) in 2005, and more than 80 percent will be treated and discharged with a recommendation for follow-up care. However, many patients, both insured and uninsured, have reported problems making timely follow-up appointments.
Brent R. Asplin, M.D., M.P.H., from Regions Hospital and HealthPartners Research Foundation, St. Paul, Minn., and colleagues examined the access to follow-up appointments according to insurance status in nine U.S. cities from May 2002 to February 2003. Eight research assistants called 499 ambulatory clinics, identifying themselves as new patients who had been seen in an ED and needed an urgent follow-up appointment within one week. Callers read from one of three clinical scenarios requiring follow-up for either pneumonia, hypertension or possible ectopic pregnancy (early pregnancy implanted outside the cavity of the uterus, such as in the Fallopian tube). The same research assistant called each clinic twice using the same scenario but reporting different insurance status.
Of the 499 clinics contacted, 430 completed the study protocol. Four hundred six (47.2 percent) of 860 total callers and 277 (64.4 percent) of 430 privately insured callers were offered appointments within a week. Callers who said they had private health insurance were more likely to receive appointments than those claiming to have Medicaid coverage (63.6 percent vs. 34.2 percent). Those claiming to have private insurance also had higher appointment rates than those who reported having no insurance but offered to pay $20 and arrange payment of balance (65.3 percent vs. 25.1 percent). Researchers found no difference in the appointment rates between callers with private insurance and those uninsured, but willing to pay cash for the entire visit fee (66.3 percent vs. 62.8 percent). The typical charge would have been about $100.
"Regardless of insurance status, 98 percent of clinics contacted in this study screened callers to determine insurance status, whereas only 28 percent attempted to determine the severity of the caller's condition," the authors write.
"These study findings suggest that reported insurance status influences access to follow-up appointments for patients with conditions requiring urgent ambulatory follow-up care," the authors write. "Although the ultimate consequences of these access barriers are not known, they may result in patients' delaying needed follow-up care, risking adverse outcomes, or requiring additional emergency care or hospitalization."
(JAMA. 2005;294:1248-1254. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: Project costs were funded by the Henry J. Kaiser Family Foundation. Dr. Asplin's work was supported by a grant from the Agency for Healthcare Research and Quality.
For More Information: Contact the JAMA/Archives Media Relations Department at 312/464-JAMA (5262) or email: mediarelations{at}jama-archives.org.
Go back to the top.
Embargoed for Release: 3 p.m. CT, Tuesday, September 13, 2005
Media Advisory: To contact Ahmedin Jemal, D.V.M., Ph.D., call David Sampson at 213-368-8523.
STUDY REVEALS TRENDS IN U.S. DEATH RATE, LEADING CAUSES OF DEATH OVER 30 YEARS
CHICAGO—The death rate from all causes of death combined decreased by 32 percent between 1970 and 2002, with the largest decreases for heart disease and stroke, but with an increase in death rates for diabetes and COPD, according to an article in the September 14 issue of JAMA.
Age-standardized death rates from all causes have decreased in the United States since the 1960s; however, the overall trend masks substantial variations in cause-specific rates and in the number of deaths occurring in different age groups from specific conditions, according to background information in the article. Understanding these trends and the relationship between the age-standardized death rates and the actual number of deaths that occur could provide valuable insight into the forces that shape the nation's health.
Ahmedin Jemal, D.V.M., Ph.D., of the American Cancer Society, Atlanta, and colleagues examined trends in death rates and number of deaths from the six leading causes in the United States and considered the relationship of these trends to disease prevention and health care in an aging population. The researchers analyzed vital statistics data on death in the United States from 1970 to 2002 from each of the 6 leading causes of death: heart disease, stroke, cancer, chronic obstructive pulmonary disease (COPD), accidents (i.e., related to transportation [motor vehicle, other land vehicles, and water, air, and space] and not related to transportation [falls, fire, and accidental poisoning]), and diabetes mellitus.
The researchers found that the age-standardized death rate (per 100,000 per year) from all causes combined decreased from 1,242 in 1970 to 845 in 2002 (32 percent decrease). The largest percentage decreases were in death rates from stroke (63 percent), heart disease (52 percent), and accidents (41 percent). The largest absolute decreases in death rates were from heart disease (262 deaths per 100,000), stroke (96 deaths per 100,000), and accidents (26 deaths per 100,000).
The death rate from all types of cancer combined increased between 1970 and 1990 and then decreased through 2002, yielding a net decline of 2.7 percent. In contrast, death rates doubled from chronic obstructive pulmonary disease over the entire time interval and increased by 45 percent from diabetes since 1987. Despite decreases in age-standardized death rates from 4 of the 6 leading causes of death, the absolute number of deaths from these conditions continues to increase, although these deaths occur at older ages.
"...the number of deaths continues to increase because of population growth and aging. It is the number of individuals affected by various conditions and the age-standardized rate that influence the planning and allocation of preventive and medical services," the authors write.
"Several important insights are suggested by these temporal trends in the death rates and number of deaths at various ages. First, the decrease in the age-standardized death rate for 4 of the 6 leading causes of death in the United States represents progress toward one of the fundamental goals of disease prevention by extending the number of years of potentially healthy life. This progress has been greater for cardiovascular disease and for accidental deaths than for cancer, yet even for cancer the age-standardized death rate has been decreasing by 1.1 percent per year since 1993. Less favorable developments are the slowing of the decline in age-standardized mortality rates from stroke and accidents since the early 1990s, and the increase in death rates from COPD and diabetes."
"The reduction in the death rate from accidents from 1970 through the early 1990s coincided with implementation of a 55 mph speed limit during the first energy crisis in the 1970s and mandated use of seat belts in most states beginning in 1984. The recent flattening of the accident mortality rate coincides with the relaxation of the maximum interstate speed limits since 1987. The biphasic [having two phases] trend in cancer mortality rates reflects both the impact of the tobacco epidemic on tobacco-related cancers through 1990, followed by reduction in cancer mortality through tobacco control and advances in early detection, in treatment, or in both. The increase in COPD death rates results largely from the long-term effects of tobacco smoking in an aging population, whereas the increase in diabetes mortality since the late 1980s reflects dramatic increases in obesity," the researchers write.
"A consequence of the large decrease in cardiovascular death rates, combined with high-birth rates that immediately followed World War II, is the growing importance of health and health care needs in an aging population. While improved treatment for chronic diseases has resulted in declining mortality rates, it has also increased the prevalence of 'treated disease' and an associated increase in health care expenditures," the authors conclude.
(JAMA. 2005;294:1255-1259. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: The American Cancer Society funded the analysis, interpretation, compilation of cancer surveillance data.
For More Information: Contact the JAMA/Archives Media Relations Department at 312/464-JAMA (5262) or email: mediarelations{at}jama-archives.org.
Go back to the top.
JAMA REPORTS
VIDEO: Windows Media | Quicktime
STENT COATED WITH DRUG CALLED PACLITAXEL MORE EFFECTIVE THAN BARE METAL STENTS IN TREATING SICKEST HEART PATIENTS
VIDEO:
NAT SOT UP FULL FOR :02
Shawn working out with punching bag
AUDIO:
"Sound of punching/kicking bag"
VIDEO:
B-ROLL
Shawn working out with punching bag
AUDIO:
FITNESS TRAINER SHAWN GRAHAM HAS WORKED OUT HARD FOR YEARS, BELIEVING IN "NO PAIN, NO GAIN." BUT TWO YEARS AGO, AT AGE 37, HE FELT A NEW KIND OF PAIN.
VIDEO:
SOT/FULL
@ :12
Super: Shawn Graham
Treated for heart disease
Runs :09
AUDIO:
"I was teaching classes, working out, and I was feeling burning sensations in my chest, a little heaviness."
VIDEO:
B-ROLL
Graphic of artery with plaque
Still photo of stents from manufacturer
Angioplasty taking place in catheter lab
Close up of screen showing stent
AUDIO:
HIS BODY MADE PLAQUE THAT WAS CLOGGING HIS HEART ARTERIES. SO DOCTORS PUT IN SEVEN OF THESE SMALL METAL TUBES, CALLED STENTS, TO HOLD OPEN THE ARTERIES. THESE STENTS ARE COATED WITH A DRUG CALLED PACLITAXEL (PACK-lih-TAX-EL) THAT PREVENTS SCAR TISSUE FROM GROWING AND CLOGGING THE ARTERY AGAIN. THE STENTS ARE PUT IN THROUGH AN ARTERY IN THE LEG TO REACH THE HEART. A SMALL BALLOON OPENS THE ARTERIES FIRST.
VIDEO:
SOT/FULL
NAT SOT UP FULL FOR :08
Close up of actual procedure on monitor as Dr. Popma describes it
AUDIO:
"The balloon is deflated and now the balloon will be removed from the body and the metallic medicated stent will be left behind in the patient."
VIDEO:
B-ROLL
Dr. Popma and colleague looking at computer screen of procedure
GFX/JAMA COVER
AUDIO:
DR. JEFFREY POPMA AND COLLEAGUES COMPARED THOSE MEDICATED STENTS TO BARE METAL STENTS WITH NO MEDICATION COATING, IN MORE THAN A THOUSAND PATIENTS WITH SERIOUS BLOCKAGES. THEIR FINDINGS APPEAR IN JAMA, THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION.
VIDEO:
SOT/FULL
@ 1:05
Super: Jeffrey Popma, M.D.
Brigham and Woman’s Hospital
Runs :13
AUDIO:
"Those patients who were treated with the bare metal stents were twice as likely to need to have another procedure in the future than were those patients who were treated with the medicated paclitaxel stent."
VIDEO:
B-ROLL
Patient in cath lab having procedure
AUDIO:
ANOTHER PROCEDURE COULD MEAN ANOTHER STENT, OR A SERIOUS SURGERY. BUT THE COATED STENT REDUCED THE NEED FOR THOSE.
VIDEO:
SOT/FULL
Jeffrey Popma, M.D.
Brigham and Woman’s Hospital
Runs :03
AUDIO:
"The results of this study are good news for patients."
VIDEO:
B-ROLL
Sean in boxing ring with sparring partner
AUDIO:
SHAWN SAYS HIS PACLITAXEL STENTS HAVE CERTAINLY BEEN GOOD NEWS TO HIM.
VIDEO:
SOT/FULL
Shawn Graham
Treated for heart disease
Runs :08
AUDIO:
"Having these medicated stents has been a blessing to me. It’s not only saved my life, but it also saved my lifestyle."
VIDEO:
B-ROLL
Sean in boxing ring with sparring partner
AUDIO:
HE’S DETERMINED NOT TO LET HEART DISEASE KNOCK HIM OUT. THIS IS MAVIS PRALL WITH THE JAMA REPORT.
